Baseline antibodies (against ANT, β1R, MHC, and CaC) and cytokines (IFN-γ, IL-4, and IL-17) were significantly higher in patients who developed DCM as compared to those who did not develop DCM. This evidence concerns the gene IL17A and familial dilated cardiomyopathy.